Floatz logo

Abi-009

Leigh Syndrome

Aadi Bioscience, Inc.Phase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the Leigh Syndrome cohort.

Asset / SponsorPhaseRating
Epi-743
PTC Therapeutics
Phase 2B
Sonlicromanol
Khondrion BV
Phase 2B
MANNITOL
Thiogenesis Therapeutics, Inc.
Phase 2CCC
Rapamycin
Matthew Demczko
Phase 2CCC
Tti-0102: Cysteamine-Pantetheine Disulfide
Thiogenesis Therapeutics, Inc.
Phase 2NR
Vatiquinone
PTC Therapeutics
Phase 2/3NR

Same molecule, other indications

Abi-009 is also rated in:

Epilepsy IntractableDormant
CC
Indicative ·
47 / 100
View asset →
neoplasmDormant
CC
Indicative ·
40 / 100
View asset →
plasma cell myelomaDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →